Skip to main content

Table 3 Relationship between selected parameters and occurrence of posttransplant CMV infection

From: Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients

Characteristics CMV infection No CMV infection p
N = 21 N = 65
Age, mean ± SD, y 51.4 ± 13.8 46.8 ± 15.6 0.244
Gender, male (%) 57.1 69.2 0.308
Type of transplant, Kidney /Kidney + pancreas (%) 24.4/25.0 75.6/75.0 0.977
Allograft function, (eGFR), mean ± SD
 Day 30 44.0 ± 15.4 50.2 ± 23.3 0.347
 Day 90 43.7 ± 17.4 52.6 ± 21.8 0.136
Blood transfusion, N Yes/No 12 /9 24 /38 0.140
Donor, D+/D- (%) 23.4/33.3 76.6/66.7 0.682
Pretransplant recipient CMV serostatus R+/R- (%) 22.4/33.1 77.6/66.9 0.410
The time of VGCV initiation after KTx (days); mean ± SD 9 ± 5 9 ± 5 0.905
The time of VGCV discontinuation after KTx (days); mean ± SD 94 ± 9 92 ± 14 0.458
Duration of antiviral prophylaxis (days); mean ± SD 85 ± 9 82 ± 15 0.382
total IgG concentration (g/L) < 7 / ≥7%
 Day 0 0.0/26.3 100.0/73.7 0.571
 Day 90 41.1/18.0 58.9/82.0 0.057
anti-CMV IgG titer (AU/ml) mean ± SD
 Day 0 138 ± 113 168 ± 109 0.803
 Day 90 113 ± 85 159 ± 109 0.087
leukocyte blood count (G/L) mean ± SD
 Day 0 7.8 ± 2.4 7.9 ± 2.3 1.000
 Day 30 8.5 ± 2.7 9.2 ± 4.0 0.800
 Day 90 6.6 ± 4.9 6.5 ± 3.2 0.080
Induction therapy (%)    0.026
 Yes basiliximab 25.8 74.2  
 Yes thymoglobulin 57.1 42.9
 None 5.9 94.1
QuantiFERON-CMV assay (IU/mL) < 0.2/≥0.2 (%)
 All time points used 42.9/15.6 57.1/84.4 0.005
 Day 7 39.0/14.6 61.0/85.4 0.015
 Day 30 40.7/9.1 59.3/90.9 0.003
 Day 90 42.8/16.4 57.2/83.6 0.008
lymphocyte blood count (G/L) < 0.8/≥0.8 (%)
 Day 0 0.0/25.3 100.0/74.7 1.000
 Day 30 42.9/21.0 57.1/79.0 0.090
 Day 90 53.8/20.0 46.2/80.0 0.015
gammaglobulin blood concentration (g/dL) < 0.8/≥0.8 (%)
 Day 0 18.2/24.8 81.8/75.2 0.623
 Day 90 41.7/5.9 58.3/94.1 0.0004